Effect of valsartan on renal handling of uric acid in healthy subjects.
OBJECTIVE
To evaluate the effect of valsartan on renal handling of uric acid in healthy subjects.


METHODS
A randomized, single-blind, placebo-controlled clinical trial was performed in twelve healthy volunteers. Six received a morning dose of valsartan 80 mg orally during 14 to 21 days and the other six received placebo. Before and after valsartan or placebo, clearance, fractional excretion and excretion uric acid rates were calculated. Presecretory reabsorption, tubular secretion and postsecretory reabsorption of uric acid were assessed by pharmacological tests using pyrazinamide or probenecid.


RESULTS
There were no differences in clearance, fractional excretion and excretion uric acid rates with valsartan and placebo. Valsartan did not affect presecretory reabsorption (p = 0.92), tubular secretion (p = 0.62) or postsecretory reabsorption (p = 0.52) of uric acid.


CONCLUSIONS
Valsartan did not significantly affect renal handling of uric acid in healthy subjects.
González-Ortiz
M
M
Medical Research Unit in Clinical Epidemiology, West National Medical Center, Mexican Institute of Social Security, Guadalajara City, Jalisco. uiec@prodigy.net.mx
Mora-Martínez
J M
JM
Martínez-Abundis
E
E
Balcázar-Muñoz
B R
BR
D000328:Adult; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D016037:Single-Blind Method; D013777:Tetrazoles / Q000494:pharmacology*; D014527:Uric Acid / Q000378:metabolism*; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
D013777:Tetrazoles; D014527:Uric Acid; D000068756:Valsartan; D014633:Valine